Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mitoxantrone hydrochloride
Drug ID BADD_D01481
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status Prescription; Discontinued
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D02166
MeSH ID D008942
PubChem ID 51082
TTD Drug ID D0R3JB
NDC Product Code 63323-132; 58598-0005
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H30Cl2N4O6
CAS Registry Number 70476-82-3
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisG1/S-specific cyclin-D1P24385T12355Not Available
ApoptosisTranscription factor JunP05412T69085Not Available
Cytogenetic investigationsDNA topoisomerase 1P11387T09826Not Available
Toxicity to various agentsEpoxide hydrolase 1P07099Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinitis22.07.03.006; 11.01.13.004--
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007--Not Available
Skin infection23.09.04.002; 11.01.12.003--
Stomatitis07.05.06.005--
Tachycardia02.03.02.007--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular arrhythmia02.03.04.006--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Ejection fraction decreased13.14.02.003--
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.001--
Infusion site phlebitis12.07.05.004; 24.05.03.002; 08.02.05.003--Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase abnormal13.04.02.005--Not Available
Antineutrophil cytoplasmic antibody decreased13.06.01.010--Not Available
Neurological symptom17.02.05.010--Not Available
Bladder disorder20.03.01.002--Not Available
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Urine analysis abnormal13.13.02.008--Not Available
Transaminases abnormal13.03.01.021--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages